FDA found GLP violations in SDWH's nonclinical testing of medical devices, raising doubts about safety data.
What happened
FDA inspected SDWH's Suzhou, China, testing facility from March 6 to March 15, 2024, to check Good Laboratory Practice (GLP), the rules for reliable nonclinical safety studies. FDA found serious failures by the study director and quality assurance unit (QAU) across multiple medical-device tests, including cytotoxicity, sensitization, hemolysis, complement activation, and implantation studies. The failures included selecting only 5 of 6 cytotoxicity results, inability to link plate-reader raw data to specific samples, incomplete archiving, unaddressed duplicate data, and a changed test-material description.
What FDA found
The study director did not ensure the protocol was followed or that data were accurately recorded and verified; for example, the firm selected only 5 of 6 cytotoxicity results for analysis.
21 CFR 58.33(a), (b)The study director could not attribute raw plate-reader data to specific samples when samples from multiple studies were tested on the same 96-well plate.
21 CFR 58.33(b)The study director did not ensure all raw data were archived; only incomplete transcribed data were archived for some cytotoxicity, complement activation, and hemolysis tests.
21 CFR 58.33(e)The study director did not document or approve a change in the test-material description in a final report compared with the protocol and raw data.
21 CFR 58.33(c), (f)Testing facility management did not ensure the quality assurance unit (QAU) communicated deviations to the study director and that corrective actions were taken and documented, including for duplicate data in MTT cytotoxicity reports.
21 CFR 58.31(c), (g)The QAU did not catch protocol deviations, verify final reports against raw data, or inspect studies at adequate intervals and immediately report problems likely to affect study integrity.
21 CFR 58.35(b)(3), (5), (6)
What FDA wants
FDA tells SDWH that its written response is inadequate and asks it to address the GLP violations, show how SOPs will be followed, add preventive audits and training, and document future deviations; the provided letter excerpt does not state a response deadline.
Who should pay attention
- medical device makers whose FDA submissions rely on SDWH test data
- sponsors of biocompatibility and nonclinical safety studies
- other GLP test labs and quality auditors
This is a summary. Read the original letter on fda.gov.